Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis.
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
Use of amiloride and multiple sclerosis: registry-based cohort studies.
A full genome search in multiple sclerosis.
Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults.
Genzyme’s once-daily, oral AUBAGIO® approved in Australia for treatment of relapsing multiple sclerosis
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Withdrawal of the marketing authorization in the European Union
Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine.
Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
Safety Study of Interferon Beta-1a for Acute Stroke
Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity.
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.
The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria.
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Alemtuzumab
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
Antigen-specific tolerance by autologous myelin Peptide-coupled cells: a phase 1 trial in multiple sclerosis.
Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.

Pages